A clinical trial update for Debio 4326, a triptorelin formulation, was recorded on September 22, 2026. The study, registered as NCT06129539 and known as the LIBELULA trial, is titled "A Study to Assess the Efficacy, Safety, and Pharmacokinetics of Debio 4326 in Pediatric Participants With Central Precocious Puberty."
The trial is listed as Phase 3 and its current status is active but not recruiting. This means the study is ongoing and enrolled participants continue to be followed, but new participants are not currently being enrolled.
The study is designed to assess efficacy, safety, and pharmacokinetics of Debio 4326 in pediatric participants diagnosed with central precocious puberty. No results have been posted with this update, and no efficacy or safety outcomes are described in the available record.
This status change reflects a procedural update in the trial's recruitment phase only. Readers should not interpret this update as indicating any particular outcome, benefit, or risk associated with the compound. Further updates may be posted as the trial progresses through subsequent phases or reports results.
For more background on this compound, see the linked compound overview.